CN110721333A - Antiallergic dressing used after anesthesia and preparation method thereof - Google Patents
Antiallergic dressing used after anesthesia and preparation method thereof Download PDFInfo
- Publication number
- CN110721333A CN110721333A CN201911033815.9A CN201911033815A CN110721333A CN 110721333 A CN110721333 A CN 110721333A CN 201911033815 A CN201911033815 A CN 201911033815A CN 110721333 A CN110721333 A CN 110721333A
- Authority
- CN
- China
- Prior art keywords
- extract
- antiallergic
- allergic
- anesthesia
- dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 206010002091 Anaesthesia Diseases 0.000 title claims abstract description 23
- 230000037005 anaesthesia Effects 0.000 title claims abstract description 23
- 239000000835 fiber Substances 0.000 claims abstract description 47
- 235000010410 calcium alginate Nutrition 0.000 claims abstract description 46
- 239000000648 calcium alginate Substances 0.000 claims abstract description 46
- 229960002681 calcium alginate Drugs 0.000 claims abstract description 46
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims abstract description 46
- 239000007863 gel particle Substances 0.000 claims abstract description 43
- 239000002131 composite material Substances 0.000 claims abstract description 35
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims description 65
- 239000000243 solution Substances 0.000 claims description 50
- 238000009987 spinning Methods 0.000 claims description 43
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 230000015271 coagulation Effects 0.000 claims description 23
- 238000005345 coagulation Methods 0.000 claims description 23
- 235000010413 sodium alginate Nutrition 0.000 claims description 21
- 239000000661 sodium alginate Substances 0.000 claims description 21
- 229940005550 sodium alginate Drugs 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 239000004745 nonwoven fabric Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 239000011259 mixed solution Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 229920000742 Cotton Polymers 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 9
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 9
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 9
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 8
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 8
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 8
- 229940041616 menthol Drugs 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 241000205585 Aquilegia canadensis Species 0.000 claims description 7
- GDESEHSRICGNDP-UHFFFAOYSA-L [Cl-].[Cl-].[Ca+2].CCO Chemical compound [Cl-].[Cl-].[Ca+2].CCO GDESEHSRICGNDP-UHFFFAOYSA-L 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000002166 wet spinning Methods 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical class [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 238000009941 weaving Methods 0.000 claims description 4
- 244000197975 Solidago virgaurea Species 0.000 claims description 3
- 235000000914 Solidago virgaurea Nutrition 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 238000013329 compounding Methods 0.000 claims description 2
- 238000012681 fiber drawing Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 230000001112 coagulating effect Effects 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 3
- 241000628997 Flos Species 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 244000293323 Cosmos caudatus Species 0.000 claims 1
- 235000005956 Cosmos caudatus Nutrition 0.000 claims 1
- 240000003146 Lobelia chinensis Species 0.000 claims 1
- 238000007605 air drying Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 238000010025 steaming Methods 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 abstract description 5
- 208000010668 atopic eczema Diseases 0.000 abstract description 5
- 230000036407 pain Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 34
- 241000110847 Kochia Species 0.000 description 6
- 241001529733 Nepeta Species 0.000 description 6
- 241000208672 Lobelia Species 0.000 description 5
- 240000004370 Pastinaca sativa Species 0.000 description 5
- 235000017769 Pastinaca sativa subsp sativa Nutrition 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 241000607059 Solidago Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000002344 surface layer Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000013530 defoamer Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种用于麻醉后的抗过敏敷料及其制备方法,属于麻醉科医用敷料技术领域,所述抗过敏敷料包括无纺布和粘接在无纺布上的载药层,所述载药层为负载有抗过敏凝胶颗粒的海藻酸钙复合纤维制备而成的,所述抗过敏凝胶颗粒包括海藻酸钙壳层和装填在海藻酸钙壳层内的抗过敏药液。本发明的敷料具有抗过敏的作用,还可以减缓患者已出现的过敏症状,同时还具有止痛杀菌的功效。The invention discloses an anti-allergic dressing used after anesthesia and a preparation method thereof, belonging to the technical field of medical dressings in anesthesia. The drug-loading layer is prepared from calcium alginate composite fibers loaded with anti-allergic gel particles, and the anti-allergic gel particles include a calcium alginate shell layer and an anti-allergic liquid filled in the calcium alginate shell layer. . The dressing of the invention has an anti-allergic effect, can also alleviate the allergic symptoms that have occurred in a patient, and also has the effect of relieving pain and sterilizing.
Description
技术领域technical field
本发明涉及麻醉科医用敷料技术领域,尤其涉及一种用于麻醉后的抗过敏敷料及其制备方法。The invention relates to the technical field of anesthesia medical dressings, in particular to an anti-allergic dressing used after anesthesia and a preparation method thereof.
背景技术Background technique
有关麻醉技术,世界上最早的文字记载是出现在我国的汉朝,由中国古代著名外科专家、中医药学家华佗发明的麻沸汤。麻沸汤为中药汤剂相当于现在的口服全麻剂,口服后患者皮肤感觉丧失而便于实施手术。后来西医发明了各种麻醉剂,如现在盛行的利多卡因、布比卡因、普鲁卡因等等。麻醉是由药物或其他方法产生的一种中枢神经和周围神经系统的可逆性功能抑制,这种抑制的特点主要是感觉特别是痛觉的丧失。Regarding anesthesia technology, the earliest written record in the world is the Mafei Decoction invented by Hua Tuo, a famous ancient Chinese surgical expert and Chinese medicine scientist, which appeared in the Han Dynasty in my country. Ma Fei Tang is a traditional Chinese medicine decoction equivalent to the current oral general anesthesia. After oral administration, the patient loses skin sensation and facilitates the operation. Later, Western medicine invented various anesthetics, such as lidocaine, bupivacaine, procaine and so on. Anesthesia is a reversible functional inhibition of the central and peripheral nervous systems produced by drugs or other methods, which is mainly characterized by loss of sensation, especially pain.
现在麻醉不仅是应用于大型手术的感觉屏蔽,还应用于创伤口的止痛,便于创伤口的清理、缝合,麻醉过程中往往需要使用敷料,例如阻滞麻醉,是将局部麻醉药物注射于神经干或主要分支周围,以阻断神经末梢的传入刺激,使该神经分布区域产生麻醉效果,退针后用敷料将穿刺点覆盖。目前常用的敷料材料有纱布、油纱、藻酸钙敷料、水胶体敷料等,其中纱布、油纱等敷料覆盖处的皮肤由于反复接触消毒液及粘性敷料覆盖,加之气温升高的季节皮肤的汗液刺激,部分病人会出现穿刺点周边皮肤因出汗等情况而影响了透明敷料的粘性屏障作用。有些病人特别是老年人,长期使用会出现敷料边缘切迹对皮肤刺激而发生的刺激性皮炎。病人表现为敷料边缘的皮肤发红、痒、痛感、水泡等症状。其中,因藻酸钙敷料具有无毒性、无免疫原性、可生物降解性等优良性能被越来越广泛的使用,但是海藻酸钙敷料因其海藻酸钙纤维自身的力学性能差、强力不匀率高的特点,可纺性差,通常采用非织造形式制成,容易造成直角方向开裂,造成敷料强度低和耐久度差,敷料会发生翘起、脱落等情况。所以,目前急需一种强度高、不易撕裂的抗过敏海藻酸钙纤维敷料。Now anesthesia is not only used for sensory shielding in major surgery, but also for pain relief of wounds, which is convenient for wound cleaning and suturing. Dressings are often used during anesthesia, such as block anesthesia, which is to inject local anesthetics into the nerve trunk. Or around the main branch to block the afferent stimulation of nerve endings, so that the nerve distribution area has an anesthetic effect, and the puncture point is covered with a dressing after the needle is withdrawn. At present, the commonly used dressing materials include gauze, oil gauze, calcium alginate dressing, hydrocolloid dressing, etc. Among them, the skin covered by gauze, oil gauze and other dressings is covered by repeated contact with disinfectant and viscous dressings, and the skin in the season when the temperature rises. Sweat is irritated, and some patients may experience sweating of the skin around the puncture point, which affects the adhesive barrier function of the transparent dressing. Some patients, especially the elderly, may experience irritant dermatitis caused by skin irritation from the edge of the dressing after long-term use. The patient presented with redness, itching, pain, blisters and other symptoms of the skin at the edge of the dressing. Among them, calcium alginate dressings are more and more widely used because of their excellent properties such as non-toxicity, non-immunogenicity, and biodegradability. It has the characteristics of high uniformity and poor spinnability. It is usually made in non-woven form, which is easy to cause cracks in the right-angle direction, resulting in low strength and poor durability of the dressing, and the dressing will warp and fall off. Therefore, there is an urgent need for an anti-allergic calcium alginate fiber dressing with high strength and not easy to tear.
发明内容SUMMARY OF THE INVENTION
有鉴于此,本发明的目的是提供一种用于麻醉后的抗过敏敷料及其制备方法,该抗过敏敷料用于麻醉后对穿刺点的覆盖,制备的敷料具有抗过敏的作用,能够减缓患者已经出现的过敏症状,同时还具有止痛杀菌的功效。In view of this, the purpose of the present invention is to provide an anti-allergic dressing after anesthesia and a preparation method thereof, the anti-allergic dressing is used to cover the puncture point after anesthesia, and the prepared dressing has anti-allergic effect and can slow down Allergic symptoms that the patient has already appeared, but also has the effect of pain relief and bactericidal.
本发明通过以下技术手段解决上述技术问题:The present invention solves the above-mentioned technical problems through the following technical means:
一种用于麻醉后的抗过敏敷料,所述抗过敏敷料包括无纺布和粘接在无纺布上的载药层,所述载药层为负载有抗过敏凝胶颗粒的海藻酸钙复合纤维制备而成的,所述抗过敏凝胶颗粒包括海藻酸钙壳层和装填在海藻酸钙壳层内的抗过敏药液。An anti-allergic dressing used after anesthesia, the anti-allergic dressing comprises a non-woven fabric and a drug-loading layer bonded on the non-woven fabric, and the drug-loading layer is calcium alginate loaded with anti-allergic gel particles The anti-allergic gel particles are prepared from composite fibers, and the anti-allergic gel particles include a calcium alginate shell layer and an anti-allergic medicinal liquid filled in the calcium alginate shell layer.
进一步,所述海藻酸钙复合纤维主要由海藻酸钠和短棉纤维按照质量比(20-25):(4-8)复合制备而成。Further, the calcium alginate composite fiber is mainly prepared by compounding sodium alginate and short cotton fiber according to the mass ratio of (20-25):(4-8).
进一步,所述海藻酸钙复合纤维和抗过敏凝胶颗粒的质量比为(24-33):(3-8),所述抗过敏凝胶颗粒的粒径为0.2-0.5mm。Further, the mass ratio of the calcium alginate composite fiber and the anti-allergic gel particles is (24-33):(3-8), and the particle size of the anti-allergic gel particles is 0.2-0.5 mm.
进一步,所述抗过敏药液包括以下成分:尼泊金乙酯、薄荷脑提取物、地肤子提取物、珍珠粉、荆芥提取物、防风提取物、金银花提取物、一枝黄花提取物、半边莲提取物。Further, the anti-allergic liquid includes the following components: ethyl paraben, menthol extract, Kochia extract, pearl powder, Nepeta extract, parsnip extract, honeysuckle extract, goldenrod flower extract, Lobelia Extract.
进一步,所述抗过敏凝胶颗粒的包括以下重量份原料:40-56份羧甲基纤维素、35-45份海藻酸钠、10份甘油、0.1份尼泊金乙酯、1-2份薄荷脑提取物、1-3份地肤子提取物、2-3份珍珠粉、5-6份荆芥提取物、3-5份防风提取物、0.5-1份金银花提取物、0.05-0.1份一枝黄花提取物、0.05-0.2份半边莲提取物。Further, the anti-allergic gel particles include the following raw materials in parts by weight: 40-56 parts of carboxymethyl cellulose, 35-45 parts of sodium alginate, 10 parts of glycerin, 0.1 part of ethylparaben, 1-2 parts of Menthol Extract, 1-3 Parts Kochia Extract, 2-3 Parts Pearl Powder, 5-6 Parts Nepeta Extract, 3-5 Parts Parsnip Extract, 0.5-1 Parts Honeysuckle Extract, 0.05-0.1 Parts Parts Solidago Extract, 0.05-0.2 Parts Lobelia Extract.
进一步,所述无纺布与载药层的面积比为1:(0.8-0.9)。Further, the area ratio of the non-woven fabric to the drug-loading layer is 1:(0.8-0.9).
进一步,本发明还公开了所述抗过敏敷料的制备方法,将短棉纤维和抗过敏凝胶颗粒加入饱和的海藻酸钠溶液中,得到的混合纺丝液经湿法纺丝机的喷丝孔中喷出至45℃的凝固浴中,析出,得到的纤维经拉伸辊牵引拉伸,得到负载有抗过敏凝胶颗粒的海藻酸钙复合纤维,将干燥后的海藻酸钙复合纤维形成载药层;将无纺布于水蒸汽下蒸制20-30min,然后干燥至含水量为30-40%,将载药层加热至80-85℃,趁热将载药层粘粘于无纺布上,得到抗过敏敷料,于常温下自然风干,密封无菌保存。Further, the present invention also discloses the preparation method of the anti-allergic dressing. The short cotton fibers and the anti-allergic gel particles are added to the saturated sodium alginate solution, and the obtained mixed spinning solution is subjected to spinning by a wet spinning machine. It is sprayed out of the hole to a coagulation bath at 45°C, and precipitated. The obtained fiber is drawn and stretched by a drawing roller to obtain a calcium alginate composite fiber loaded with anti-allergic gel particles, and the dried calcium alginate composite fiber is formed. Drug-loading layer; steam the non-woven fabric under water vapor for 20-30min, then dry to a water content of 30-40%, heat the drug-loading layer to 80-85°C, and stick the drug-loading layer to the The anti-allergic dressing is obtained on the spinning cloth, which is naturally air-dried at room temperature, and sealed and stored aseptically.
进一步,所述载药层的制备包括以下步骤:Further, the preparation of the drug-loading layer includes the following steps:
混合纺丝液制备:将海藻酸钠缓慢溶解于去离子水中,以400-600rpm的速率搅拌1-2h,得到海藻酸钠溶液,将短棉纤维、消泡剂加入海藻酸钠溶液中,以1000-1500rpm搅拌1-2h后,再加入抗过敏凝胶颗粒,以300-500rpm的速率搅拌分散20-30min后,得到混合纺丝液;Preparation of mixed spinning solution: slowly dissolve sodium alginate in deionized water, stir at a speed of 400-600rpm for 1-2h to obtain sodium alginate solution, add short cotton fiber and defoamer to the sodium alginate solution, After stirring at 1000-1500rpm for 1-2h, add anti-allergic gel particles, and stir and disperse at a speed of 300-500rpm for 20-30min to obtain a mixed spinning solution;
凝固浴制备:配制乙醇-氯化钙混合溶液,并调节混合溶液pH=6.5-7,得到凝固浴;Preparation of coagulation bath: prepare a mixed solution of ethanol-calcium chloride, and adjust the pH of the mixed solution=6.5-7 to obtain a coagulation bath;
海藻酸钙复合纤维制备:在环境温度为30℃、相对湿度≤65%的条件下,湿法纺丝机的喷丝孔喷出混合纺丝液进入45℃的凝固浴中,单喷头纺丝速率为10ml/h,混合纺丝液于凝固浴中析出,得到纤维,经纤维拉伸辊牵引拉伸至1倍后用蒸馏水清洗,干燥后得到负载有抗过敏凝胶颗粒的海藻酸钙复合纤维,所述海藻酸钙复合纤维的直径为0.6-1mm;Preparation of calcium alginate composite fiber: Under the conditions of ambient temperature of 30 °C and relative humidity of ≤65%, the spinning hole of the wet spinning machine ejects the mixed spinning solution into a coagulation bath at 45 °C, and spins with a single nozzle. The rate is 10ml/h, and the mixed spinning solution is precipitated in the coagulation bath to obtain fibers, which are stretched to 1 times by the fiber drawing roller, washed with distilled water, and dried to obtain a calcium alginate composite loaded with anti-allergic gel particles. Fiber, the diameter of the calcium alginate composite fiber is 0.6-1mm;
载药层制备:将干燥后的海藻酸钙复合纤维采用经纬编织方法编织成厚度为0.5-0.8cm的载药层。Preparation of drug-loaded layer: the dried calcium alginate composite fiber is woven into a drug-loaded layer with a thickness of 0.5-0.8 cm by warp and weft weaving.
进一步,所述凝固浴与混合纺丝液的体积比为3:1。Further, the volume ratio of the coagulation bath to the mixed spinning solution is 3:1.
进一步,乙醇-氯化钙混合溶液中乙醇浓度为45-55wt%,所述氯化钙浓度为4-5wt%。Further, the ethanol concentration in the ethanol-calcium chloride mixed solution is 45-55 wt %, and the calcium chloride concentration is 4-5 wt %.
进一步,所述抗过敏凝胶颗粒的制备步骤如下:Further, the preparation steps of the anti-allergic gel particles are as follows:
将羧甲基纤维素钠加入去离子水中,待完全溶解后加入甘油、尼泊金乙酯搅拌均匀,再加入薄荷脑提取物、地肤子提取物、珍珠粉、荆芥提取物、防风提取物、金银花提取物、一枝黄花提取物、半边莲提取物混合成糊状物,将糊状物加入3-5wt%的海藻酸钠溶液中,采用25kHz的超声波分散成悬浮液,将悬浮液滴入饱和的乳酸钙溶液中,捞出,得到抗过敏凝胶颗粒。Add sodium carboxymethyl cellulose into deionized water, after it is completely dissolved, add glycerin and ethyl paraben and stir well, then add menthol extract, Kochia extract, pearl powder, Nepeta extract, and wind extract extract, honeysuckle extract, goldenrod extract, lobelia extract are mixed into a paste, the paste is added to 3-5wt% sodium alginate solution, dispersed into a suspension by 25kHz ultrasonic wave, the suspension droplets Put it into saturated calcium lactate solution, and remove it to obtain anti-allergic gel particles.
本发明提供的一种用于麻醉后的抗过敏敷料及其制备方法,有益效果如下:An anti-allergic dressing for anesthesia and a preparation method thereof provided by the present invention have the following beneficial effects:
一、本发明的抗过敏敷料用于固定静脉导管,敷料的双层结构中的表层为载药层,载药层直接接触皮肤,底层为医用无纺布;医用无纺布的阻菌效果和透气效果良好,并且防水性和伸缩性都较好,且面积大于载药层,所以底层将表层完全覆盖住,可以减少细菌、液体的侵入,而表层的载药层负载有抗过敏药液,可以避免患者对底层于载药层外侧的粘胶过敏,若已经发生过敏症状,可以缓解过敏的不良反应。1. The anti-allergic dressing of the present invention is used for fixing intravenous catheters. The surface layer in the double-layer structure of the dressing is a drug-carrying layer, the drug-carrying layer directly contacts the skin, and the bottom layer is a medical non-woven fabric; the antibacterial effect of the medical non-woven fabric and the The ventilation effect is good, and the waterproof and stretchability are good, and the area is larger than the drug-loading layer, so the bottom layer completely covers the surface layer, which can reduce the invasion of bacteria and liquid, and the drug-loading layer of the surface layer is loaded with anti-allergic liquid. It can prevent the patient from being allergic to the adhesive on the outer side of the drug-loading layer. If allergic symptoms have already occurred, the allergic adverse reactions can be alleviated.
二、海藻酸钙复合纤维无毒无害,是一种纯天然的绿色材料,可以将放置有静脉导管伤口处的渗出液吸收,去除细菌的滋生场所,还可以吸附细菌达到抗菌的目的。海藻酸钙复合纤维制备的时候将海藻酸钠和短棉纤维制备的混合纺丝液与抗过敏凝胶颗粒混合制备出来的海藻酸钙复合纤维上负载或者内部包裹有粒径为0.2-0.5mm的抗过敏凝胶颗粒,海藻酸钙复合纤维不仅具有抗菌的效果还具有抗过敏的的优点,而短棉纤维增加了海藻酸钙复合纤维的韧性。2. Calcium alginate composite fiber is non-toxic and harmless. It is a pure natural green material. It can absorb the exudate from the wound where the venous catheter is placed, remove the breeding place of bacteria, and can also absorb bacteria to achieve the purpose of antibacterial. When the calcium alginate composite fiber is prepared, the mixed spinning solution prepared by sodium alginate and short cotton fiber is mixed with anti-allergic gel particles. The anti-allergic gel particles, calcium alginate composite fiber not only has antibacterial effect but also has the advantages of anti-allergic, and short cotton fiber increases the toughness of calcium alginate composite fiber.
三、抗过敏凝胶颗粒里面含有多种中药提取物,具有抗过敏、消炎、抗菌、止痛、止痒的功效,与海藻酸钠混合制备成为悬浮液后滴加进乳酸钙溶液中,形成外部为海藻酸钙凝胶,内部为抗过敏药液的抗过敏凝胶颗粒,海藻酸钙凝胶具有一定的缓释作用,可以延长抗过敏药液的药效,达到持续给药的目的。3. The anti-allergic gel particles contain a variety of traditional Chinese medicine extracts, which have anti-allergic, anti-inflammatory, antibacterial, analgesic, and antipruritic effects. They are mixed with sodium alginate to prepare a suspension and then added dropwise to the calcium lactate solution to form an external It is calcium alginate gel with anti-allergic gel particles inside of anti-allergic liquid. Calcium alginate gel has a certain slow-release effect, which can prolong the efficacy of anti-allergic liquid and achieve the purpose of continuous administration.
具体实施方式Detailed ways
以下将结合具体实施例本发明进行详细说明:The present invention will be described in detail below in conjunction with specific embodiments:
实施例1:抗过敏敷料制备一Example 1: Anti-allergic dressing preparation one
制备抗过敏敷料应制备抗过敏凝胶颗粒,其制备方法如下:The preparation of anti-allergic dressing should prepare anti-allergic gel particles, and its preparation method is as follows:
将40g羧甲基纤维素钠加入500ml去离子水搅拌,待完全溶解后加入10g甘油、0.1g尼泊金乙酯搅拌均匀,再加入1g薄荷脑提取物、2g地肤子提取物、3g珍珠粉、5g荆芥提取物、3g防风提取物、0.5g金银花提取物、0.1g一枝黄花提取物、0.2g半边莲提取物混合成糊状物,将糊状物加入35g海藻酸钠制备的浓度为4wt%的海藻酸钠溶液中,采用25kHz的超声波分散成悬浮液,将悬浮液滴入饱和的乳酸钙溶液中,过滤得到抗过敏凝胶颗粒。经检测,制备得到的抗过敏凝胶颗粒的粒径为0.2-0.5mm。Add 40g of sodium carboxymethyl cellulose to 500ml of deionized water and stir. After it is completely dissolved, add 10g of glycerin and 0.1g of ethylparaben and stir evenly. Then add 1g of menthol extract, 2g of Kochia radix extract, and 3g of pearl. Powder, 5g Nepeta extract, 3g Parsnip extract, 0.5g Honeysuckle extract, 0.1g Solidago extract, 0.2g Lobelia extract were mixed into a paste, and the paste was added to 35g sodium alginate to prepare the concentration In a 4wt% sodium alginate solution, 25kHz ultrasonic wave is used to disperse into a suspension, drop the suspension into a saturated calcium lactate solution, and filter to obtain anti-allergic gel particles. After testing, the particle size of the prepared antiallergic gel particles is 0.2-0.5 mm.
制备完成抗过敏凝胶颗粒后制备载药层,其制备方法如下:After the antiallergic gel particles are prepared, the drug-loading layer is prepared, and the preparation method is as follows:
混合纺丝液制备:将200g海藻酸钠缓慢溶解于2000ml去离子水中,以400rpm的速率搅拌2h,得到饱和的海藻酸钠溶液,将40g 0.5-1mm长度的短棉纤维、2g DSA-5消泡剂加入饱和的海藻酸钠溶液中,以1000rpm搅拌2h后,再加入制备的30g抗过敏凝胶颗粒,以300rpm的速率搅拌20min后,得到混合纺丝液;Preparation of mixed spinning solution: 200g of sodium alginate was slowly dissolved in 2000ml of deionized water, stirred at a speed of 400rpm for 2h to obtain a saturated sodium alginate solution, and 40g of 0.5-1mm long short cotton fibers and 2g of DSA-5 were eliminated. The foaming agent was added to the saturated sodium alginate solution, and after stirring at 1000 rpm for 2 hours, 30 g of the prepared anti-allergic gel particles were added, and after stirring at a speed of 300 rpm for 20 minutes, a mixed spinning solution was obtained;
凝固浴制备:配制乙醇-氯化钙混合溶液,其中乙醇浓度为45wt%,氯化钙浓度为5wt%,并调节混合溶液pH=6.5,得到凝固浴,凝固浴与混合纺丝液的体积比为3:1;Preparation of coagulation bath: prepare a mixed solution of ethanol-calcium chloride, wherein the concentration of ethanol is 45wt%, the concentration of calcium chloride is 5wt%, and the pH of the mixed solution is adjusted to 6.5 to obtain a coagulation bath, and the volume ratio of the coagulation bath to the mixed spinning solution is 3:1;
海藻酸钙复合纤维制备:在环境温度为30℃、相对湿度≤65%的条件下,湿法纺丝机的喷丝孔喷出混合纺丝液进入45℃的凝固浴中,单喷头的纺丝速率为10ml/h,纺丝电压控制为15kv,纺丝液于凝固浴中析出,得到纤维,并经过拉伸辊牵引拉伸至1倍后用蒸馏水清洗,于35℃干燥后得到负载有抗过敏凝胶颗粒的海藻酸钙复合纤维,经测量,海藻酸钙复合纤维的直径为1mm左右;Preparation of calcium alginate composite fiber: Under the conditions of ambient temperature of 30 °C and relative humidity of ≤65%, the spinning hole of the wet spinning machine ejects the mixed spinning solution into the coagulation bath at 45 °C, and the spinning of single nozzle The spinning rate is 10ml/h, the spinning voltage is controlled to 15kv, the spinning solution is precipitated in the coagulation bath, and the fiber is obtained, which is stretched to 1 times by the drawing roller, washed with distilled water, and dried at 35 °C to obtain a loaded fiber. The calcium alginate composite fiber of the anti-allergic gel particles is measured, and the diameter of the calcium alginate composite fiber is about 1mm;
载药层制备:将干燥后的海藻酸钙复合纤维采用经纬编织方法编织成宽度为5×5cm,厚度为0.8cm的矩形载药层。Preparation of drug-loading layer: The dried calcium alginate composite fiber is woven into a rectangular drug-loading layer with a width of 5×5cm and a thickness of 0.8cm by warp and weft knitting.
抗过敏敷料制备:Anti-allergic dressing preparation:
将6.2×6.2cm医用无纺布于水蒸汽下蒸制20min,然后取出,干燥至含水量为30%,将制备的将载药层水浴加热至80℃,趁热将载药层粘粘于无纺布上,压制30s后于常温下自然风干,密封无菌保存。Steam the 6.2×6.2cm medical non-woven fabric under water vapor for 20min, then take it out, dry it to a water content of 30%, heat the prepared drug-loading layer in a water bath to 80°C, and stick the drug-loading layer on the On the non-woven fabric, after pressing for 30s, air-dry naturally at room temperature, and seal it for aseptic storage.
实施例2:抗过敏敷料制备二Example 2: Anti-allergic dressing preparation II
制备抗过敏敷料应制备抗过敏凝胶颗粒,其制备方法如下:The preparation of anti-allergic dressing should prepare anti-allergic gel particles, and its preparation method is as follows:
将50g羧甲基纤维素钠加入500ml去离子水搅拌,待完全溶解后加入10g甘油、0.1g尼泊金乙酯搅拌均匀,再加入2g薄荷脑提取物、3g地肤子提取物、2g珍珠粉、6g荆芥提取物、4g防风提取物、0.5g金银花提取物、0.05g一枝黄花提取物、0.05g半边莲提取物混合成糊状物,将糊状物加入40g海藻酸钠制备的浓度为3wt%的海藻酸钠溶液中,采用25kHz的超声波分散成悬浮液,将悬浮液滴入饱和的乳酸钙溶液中,过滤得到抗过敏凝胶颗粒。经检测,制备得到的抗过敏凝胶颗粒的粒径为0.2-0.5mm。Add 50g of sodium carboxymethyl cellulose to 500ml of deionized water and stir. After it is completely dissolved, add 10g of glycerin and 0.1g of ethylparaben and stir evenly. Then add 2g of menthol extract, 3g of Kochia radix extract, and 2g of pearl. Powder, 6g Nepeta extract, 4g Parsnip extract, 0.5g Honeysuckle extract, 0.05g Solidago extract, 0.05g Lobelia extract were mixed into a paste, and the paste was added to 40g sodium alginate to prepare the concentration In 3wt% sodium alginate solution, 25kHz ultrasonic wave is used to disperse into a suspension, drop the suspension into a saturated calcium lactate solution, and filter to obtain anti-allergic gel particles. After testing, the particle size of the prepared antiallergic gel particles is 0.2-0.5 mm.
制备完成抗过敏凝胶颗粒后制备载药层,其制备方法如下:After the antiallergic gel particles are prepared, the drug-loading layer is prepared, and the preparation method is as follows:
混合纺丝液制备:将250g海藻酸钠缓慢溶解于2500ml去离子水中,以500rpm的速率搅拌1.5h,得到饱和的海藻酸钠溶液,将80g0.5-1mm长度的短棉纤维、2g DSA-5消泡剂加入饱和的海藻酸钠溶液中,以1200rpm搅拌1h后,再加入制备的70g抗过敏凝胶颗粒,以300rpm的速率搅拌25min后得到混合纺丝液;Preparation of mixed spinning solution: Slowly dissolve 250g of sodium alginate in 2500ml of deionized water, stir at a rate of 500rpm for 1.5h to obtain a saturated sodium alginate solution, mix 80g of 0.5-1mm long short cotton fibers, 2g of DSA- 5. The defoamer is added to the saturated sodium alginate solution, and after stirring at 1200 rpm for 1 hour, 70 g of the prepared anti-allergic gel particles are added, and the mixed spinning solution is obtained after stirring at a speed of 300 rpm for 25 minutes;
凝固浴制备:配制乙醇-氯化钙混合溶液,其中乙醇浓度为50wt%,氯化钙浓度为4wt%50wt%乙醇-4wt%氯化钙混合溶液,并调节混合溶液pH=7,得到凝固浴,凝固浴与混合纺丝液的体积比为3:1;Preparation of coagulation bath: prepare a mixed solution of ethanol-calcium chloride, wherein the concentration of ethanol is 50wt%, the concentration of calcium chloride is 4wt%, the concentration of 50wt% ethanol-4wt% calcium chloride mixed solution, and the pH of the mixed solution is adjusted to 7 to obtain a coagulation bath , the volume ratio of coagulation bath and mixed spinning solution is 3:1;
海藻酸钙复合纤维制备:在环境温度为30℃、相对湿度≤65%的条件下,湿法纺丝机的喷丝孔喷出混合纺丝液进入45℃的凝固浴中,单喷头的纺丝速率为10ml/h,纺丝电压控制为15kv,纺丝液于凝固浴中析出,得到纤维,并经过拉伸辊牵引拉伸至1倍后用蒸馏水清洗,于30℃干燥后得到负载有抗过敏凝胶颗粒的海藻酸钙复合纤维,经测量,海藻酸钙复合纤维的直径0.9mm左右;Preparation of calcium alginate composite fiber: Under the conditions of ambient temperature of 30 °C and relative humidity of ≤65%, the spinning hole of the wet spinning machine ejects the mixed spinning solution into the coagulation bath at 45 °C, and the spinning of single nozzle The spinning rate was 10ml/h, the spinning voltage was controlled to 15kv, the spinning solution was precipitated in the coagulation bath, and the fiber was obtained, which was stretched to 1 times by the drawing roller, washed with distilled water, and dried at 30 °C to obtain a loaded fiber. The calcium alginate composite fiber of the anti-allergic gel particles is measured, and the diameter of the calcium alginate composite fiber is about 0.9mm;
载药层制备:将干燥后的海藻酸钙复合纤维采用经纬编织方法编织成宽度为5×5cm,厚度为0.5cm的矩形载药层。Preparation of drug-loaded layer: The dried calcium alginate composite fiber is woven into a rectangular drug-loaded layer with a width of 5×5cm and a thickness of 0.5cm by warp and weft weaving.
抗过敏敷料制备:Anti-allergic dressing preparation:
将5.6×5.6cm医用无纺布于水蒸汽下蒸制30min,然后取出,干燥至含水量为35%,将制备的将载药层水浴加热至82℃,趁热将载药层粘粘于无纺布上,压制30s后于常温下自然风干,密封无菌保存。The 5.6×5.6cm medical non-woven fabric was steamed under water vapor for 30min, then taken out, dried to a water content of 35%, heated to 82°C in a water bath of the prepared drug-loaded layer, and then adhered to the drug-loaded layer while it was still hot. On the non-woven fabric, after pressing for 30s, air-dry naturally at room temperature, and seal it for aseptic storage.
实施例3:抗过敏敷料制备三Example 3: Anti-allergic dressing preparation three
制备抗过敏敷料应制备抗过敏凝胶颗粒,其制备方法如下:The preparation of anti-allergic dressing should prepare anti-allergic gel particles, and its preparation method is as follows:
将60g羧甲基纤维素钠加入500ml去离子水搅拌,待完全溶解后加入10g甘油、0.1g尼泊金乙酯搅拌均匀,再加入2g薄荷脑提取物、1g地肤子提取物、2g珍珠粉、6g荆芥提取物、5g防风提取物、1g金银花提取物、0.1g一枝黄花提取物、0.1g半边莲提取物混合成糊状物,将糊状物加入45g海藻酸钠制备的浓度为3wtwt%的海藻酸钠溶液中,采用25kHz的超声波分散成悬浮液,将悬浮液滴入饱和的乳酸钙溶液中,过滤得到抗过敏凝胶颗粒。经检测,制备得到的抗过敏凝胶颗粒的粒径为0.2-0.5mm。Add 60g of sodium carboxymethyl cellulose to 500ml of deionized water and stir. After it is completely dissolved, add 10g of glycerin and 0.1g of ethyl paraben and stir evenly. Then add 2g of menthol extract, 1g of Kochia seed extract and 2g of pearl. Powder, 6g Nepeta extract, 5g Parsnip extract, 1g honeysuckle extract, 0.1g Solidago extract, 0.1g Lobelia extract were mixed into a paste, and the paste was added to 45g sodium alginate to prepare a concentration of In 3wtwt% sodium alginate solution, 25kHz ultrasonic wave is used to disperse into a suspension, drop the suspension into a saturated calcium lactate solution, and filter to obtain anti-allergic gel particles. After testing, the particle size of the prepared antiallergic gel particles is 0.2-0.5 mm.
制备完成抗过敏凝胶颗粒后制备载药层,其制备方法如下:After the antiallergic gel particles are prepared, the drug-loading layer is prepared, and the preparation method is as follows:
混合纺丝液制备:将200g海藻酸钠缓慢溶解于2000ml去离子水中,以600rpm的速率搅拌2h,得到饱和的海藻酸钠溶液,将60g 0.5-1mm长度的短棉纤维、2g DSA-5消泡剂加入饱和的海藻酸钠溶液中,以1500rpm搅拌1h后,再加入制备的80g抗过敏凝胶颗粒,以300rpm的速率搅拌30min后得到混合纺丝液;Preparation of mixed spinning solution: slowly dissolve 200g of sodium alginate in 2000ml of deionized water, stir at a rate of 600rpm for 2h to obtain a saturated sodium alginate solution, dissolve 60g of 0.5-1mm long short cotton fibers and 2g of DSA-5. The foaming agent was added to the saturated sodium alginate solution, and after stirring at 1500 rpm for 1 hour, 80 g of the prepared anti-allergic gel particles were added, and the mixed spinning solution was obtained after stirring at a speed of 300 rpm for 30 minutes;
凝固浴制备:配制乙醇-氯化钙混合溶液,其中乙醇浓度为55wt%,氯化钙浓度为4wt%,并调节混合溶液pH=7,得到凝固浴,凝固浴与混合纺丝液的体积比为3:1;Preparation of coagulation bath: prepare a mixed solution of ethanol-calcium chloride, wherein the concentration of ethanol is 55wt%, the concentration of calcium chloride is 4wt%, and the pH of the mixed solution is adjusted to 7 to obtain a coagulation bath, the volume ratio of the coagulation bath to the mixed spinning solution is 3:1;
海藻酸钙复合纤维制备:在环境温度为30℃、相对湿度≤65%的条件下,湿法纺丝机的喷丝孔喷出混合纺丝液进入45℃的凝固浴中,单喷头的纺丝速率为10ml/h,纺丝电压控制为15kv,纺丝液于凝固浴中析出,得到纤维,并经过拉伸辊牵引拉伸至1倍后用蒸馏水清洗,于30℃干燥后得到负载有抗过敏凝胶颗粒的海藻酸钙复合纤维,经测量,海藻酸钙复合纤维的直径0.7mm左右;Preparation of calcium alginate composite fiber: Under the conditions of ambient temperature of 30 °C and relative humidity of ≤65%, the spinning hole of the wet spinning machine ejects the mixed spinning solution into the coagulation bath at 45 °C, and the spinning of single nozzle The spinning rate was 10ml/h, the spinning voltage was controlled to 15kv, the spinning solution was precipitated in the coagulation bath, and the fiber was obtained, which was stretched to 1 times by the drawing roller, washed with distilled water, and dried at 30 °C to obtain a loaded fiber. The calcium alginate composite fiber of the anti-allergic gel particles is measured, and the diameter of the calcium alginate composite fiber is about 0.7mm;
载药层制备:将干燥后的海藻酸钙复合纤维采用经纬编织方法编织成宽度为5×5cm,厚度为0.7cm的矩形载药层。Preparation of drug-loading layer: The dried calcium alginate composite fiber is woven into a rectangular drug-loading layer with a width of 5×5cm and a thickness of 0.7cm by warp and weft weaving.
抗过敏敷料制备:Anti-allergic dressing preparation:
将6×6cm医用无纺布于水蒸汽下蒸制25min,然后取出,干燥至含水量为40%,将制备的将载药层水浴加热至85℃,趁热将载药层粘粘于无纺布上,压制30s后于常温下自然风干,密封无菌保存。Steam the 6×6cm medical non-woven fabric under water vapor for 25min, then take it out, dry it to a moisture content of 40%, heat the prepared drug-loading layer in a water bath to 85°C, and stick the drug-loading layer to the non-woven fabric while it is still hot. On the spinning cloth, after pressing for 30s, air-dry naturally at room temperature, and seal it for aseptic storage.
将实施例1-3制备的抗过敏敷料进行测量,干抗过敏敷料断裂强度3.0~3.5cN/dtex,湿抗过敏敷料断裂强度为2.0~2.9cN/dtex,说明制备的抗过敏敷料强度够高,持久耐用。The anti-allergic dressings prepared in Examples 1-3 were measured, and the breaking strength of the dry anti-allergic dressing was 3.0-3.5 cN/dtex, and the breaking strength of the wet anti-allergic dressing was 2.0-2.9 cN/dtex, indicating that the prepared anti-allergic dressing was strong enough ,Durable.
以上实施例仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的宗旨和范围,其均应涵盖在本发明的权利要求范围当中。本发明未详细描述的技术、形状、构造部分均为公知技术。The above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to the preferred embodiments, those of ordinary skill in the art should understand that the technical solutions of the present invention can be modified or equivalently replaced. Without departing from the spirit and scope of the technical solutions of the present invention, all of them should be included in the scope of the claims of the present invention. The technology, shape, and structural part that are not described in detail in the present invention are all well-known technologies.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911033815.9A CN110721333A (en) | 2019-10-25 | 2019-10-25 | Antiallergic dressing used after anesthesia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911033815.9A CN110721333A (en) | 2019-10-25 | 2019-10-25 | Antiallergic dressing used after anesthesia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110721333A true CN110721333A (en) | 2020-01-24 |
Family
ID=69222235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911033815.9A Pending CN110721333A (en) | 2019-10-25 | 2019-10-25 | Antiallergic dressing used after anesthesia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110721333A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060211972A1 (en) * | 2003-03-28 | 2006-09-21 | Brian Nielsen | Wound dressing |
| WO2009141633A2 (en) * | 2008-05-23 | 2009-11-26 | Convatec Technologies Inc. | Polysaccharide nanofibres having antimicrobial properties |
| CN103436992A (en) * | 2013-08-29 | 2013-12-11 | 浙江理工大学 | Method for preparing nano drug-carrying capsule-loaded alginate fibers |
| CN105169137A (en) * | 2015-10-23 | 2015-12-23 | 东莞市达庆医疗器械有限公司 | Antiallergic gel dressing and preparation method thereof |
| CN106975095A (en) * | 2017-04-11 | 2017-07-25 | 南阳师范学院 | A kind of antibacterial medical auxiliary material and preparation method thereof |
| CN107469131A (en) * | 2017-08-29 | 2017-12-15 | 北京化工大学常州先进材料研究院 | A kind of calcium alginate biology based composite dressing for medical use and preparation method thereof |
-
2019
- 2019-10-25 CN CN201911033815.9A patent/CN110721333A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060211972A1 (en) * | 2003-03-28 | 2006-09-21 | Brian Nielsen | Wound dressing |
| WO2009141633A2 (en) * | 2008-05-23 | 2009-11-26 | Convatec Technologies Inc. | Polysaccharide nanofibres having antimicrobial properties |
| CN103436992A (en) * | 2013-08-29 | 2013-12-11 | 浙江理工大学 | Method for preparing nano drug-carrying capsule-loaded alginate fibers |
| CN105169137A (en) * | 2015-10-23 | 2015-12-23 | 东莞市达庆医疗器械有限公司 | Antiallergic gel dressing and preparation method thereof |
| CN106975095A (en) * | 2017-04-11 | 2017-07-25 | 南阳师范学院 | A kind of antibacterial medical auxiliary material and preparation method thereof |
| CN107469131A (en) * | 2017-08-29 | 2017-12-15 | 北京化工大学常州先进材料研究院 | A kind of calcium alginate biology based composite dressing for medical use and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104758977B (en) | A kind of alginate dressing for treating bedsore and preparation method thereof | |
| CN107898716B (en) | A kind of preparation method of nanofiber dry mask | |
| CN103893815B (en) | A kind of scalds and burns dressing utilizing coaxial electrostatic spinning legal system standby and preparation method thereof | |
| CN103394114B (en) | A kind of preparation method of medical dressing chitosan-based superfine fiber carrier material | |
| CN108187120B (en) | A kind of anesthesiology medical analgesic and hemostatic dressing and preparation method thereof | |
| CN103055344B (en) | Bacterial cellulose/chitosan composite medical dressing and preparation method thereof | |
| CN103550817B (en) | A kind of Bacterial cellulose/shitosan composite sponge dressing and preparation method thereof | |
| CN105970327B (en) | A kind of health care regenerated celulose fibre containing stone needle and preparation method thereof | |
| CN107237005B (en) | A kind of alginic acid and chitosan bicomponent fiber and preparation method thereof | |
| CN110787317A (en) | Department of anesthesia uses hemostatic sponge | |
| CN104383585B (en) | A kind of three-dimensional manometer composite adhesive bandage and preparation and application thereof | |
| CN105031714A (en) | Adhesive bandage and method for manufacturing same | |
| CN107130333A (en) | A kind of alginic acid and chitosan shuffling fiber and preparation method thereof | |
| CN105251042A (en) | Medical absorbable polyglycolic acid (PGA) operation suture line and preparing method | |
| CN110433322A (en) | A kind of the wet process spunlace non-woven spontaneous heating dressing and production technology of medicine film of generating heat | |
| CN114259598B (en) | Preparation method of antibacterial healing-promoting wound dressing | |
| CN102995295B (en) | Panax pseudo-ginseng non-woven fabrics and method for preparing same | |
| CN105879106A (en) | Graphene medical cotton and preparation method thereof | |
| CN110721333A (en) | Antiallergic dressing used after anesthesia and preparation method thereof | |
| CN110917404B (en) | Pain relieving type double-layer artificial skin, preparation device and preparation method | |
| CN104324412A (en) | Bamboo chitosan functional dressing | |
| CN111249515A (en) | Antibacterial, anti-inflammatory and biomedical dressing for promoting wound healing and preparation method thereof | |
| CN107261189B (en) | Preparation method of sisal fiber environment-friendly medical gauze | |
| CN107412520A (en) | A kind of antibacterial anti hemorrhagic ointment, medicine and preparation method thereof | |
| CN110042494A (en) | A kind of functional fibre combination process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200124 |
|
| RJ01 | Rejection of invention patent application after publication |